Resolution of SLC6A1 variable expressivity in a multi-generational family using deep clinical phenotyping and Drosophila models
Authors:
- Kristy L. JayKJKristy L. Jay
- Nikhita GogateNGNikhita Gogate
- Kim EzellKEKim Ezell
- Jonathan C. AndrewsJAJonathan C. Andrews
- Sharayu V. JangamSJSharayu V. Jangam
- Paige I. HallPHPaige I. Hall
- Hongling PanHPHongling Pan
- Kelvin PhamKPKelvin Pham
- Ryan GermanRGRyan German
- Vanessa GomezVGVanessa Gomez
- Emily Jellinek-RussoEJEmily Jellinek-Russo
- Eric StorchESEric Storch
Preprint
Abstract
Purpose: Variants in SLC6A1 result in a rare neurodevelopmental disorder characterized by a variable clinical presentation of symptoms including developmental delay, epilepsy, motor dysfunction, and autism spectrum disorder. SLC6A1 haploinsufficiency has been confirmed as the predominant pathway of SLC6A1- related neurodevelopmental disorders (NDDs), however, the molecular mechanism underlying the variable clinical presentation remains unclear. Methods: Here, through work of the Undiagnosed Diseases Network, we identify an undiagnosed individual with an inherited p.(A334S) variant of uncertain significance. To resolve this case and better understand the variable expressivity with SLC6A1 , we assess the phenotypes of the proband with a cohort of cases diagnosed with SLC6A1- related NDDs. We then create an allelic series in the Drosophila melanogaster to functionally characterize case variants. Results: We identify significant clinical overlap between the unsolved case and confirmed cases of SLC6A1- related NDDs and find a mild to severe clinical presentation associated with missense variants. We confirm phenotypes in flies expressing SLC6A1 variants consistent with a partial loss-of-function mechanism. Conclusion: We conclude that the p.(A334S) variant is a hypomorphic allele and begin to elucidate the underlying variability in SLC6A1 -related NDDs. These insights will inform clinical diagnosis, prognosis, treatment and inform therapeutic design for those living with SLC6A1- related NDDs.Keywords
This publication has 33 references indexed in Scilit:
- Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1 variantsThe American Journal of Human Genetics, 2024
- Synthetic Assembly DNA Cloning to Build Plasmids for Multiplexed Transgenic Selection, Counterselection or Any Other Genetic Strategies Using Drosophila melanogasterCurrent Protocols, 2023
- Astrocytic GABA transporter 1 deficit in novel SLC6A1 variants mediated epilepsy: Connected from protein destabilization to seizures in mice and humansNeurobiology of Disease, 2022
- Astrocytic GABA transporter controls sleep by modulating GABAergic signaling in Drosophila circadian neuronsCurrent Biology, 2022
- Multiplexed drug-based selection and counterselection genetic manipulations in DrosophilaCell Reports, 2021
- SLC6A1 gene involvement in susceptibility to attention-deficit/hyperactivity disorder: A case-control study and gene-environment interactionProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2017
- The Undiagnosed Diseases Network: Accelerating Discovery about Health and DiseaseThe American Journal of Human Genetics, 2017
- Mutations in the GABA Transporter SLC6A1 Cause Epilepsy with Myoclonic-Atonic SeizuresThe American Journal of Human Genetics, 2015
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in Medicine, 2015
- GABA transporters in the mammalian cerebral cortex: localization, development and pathological implicationsBrain Research Reviews, 2004